16,565 Shares in Integer Holdings Co. (NYSE:ITGR) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new position in shares of Integer Holdings Co. (NYSE:ITGR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 16,565 shares of the medical equipment provider’s stock, valued at approximately $2,195,000.

Other large investors have also bought and sold shares of the company. Blue Trust Inc. grew its holdings in Integer by 4.4% during the 4th quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock worth $220,000 after acquiring an additional 71 shares during the period. HighTower Advisors LLC grew its holdings in Integer by 0.8% during the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock worth $1,579,000 after acquiring an additional 90 shares during the period. State of New Jersey Common Pension Fund D grew its stake in shares of Integer by 0.9% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 15,722 shares of the medical equipment provider’s stock valued at $2,083,000 after buying an additional 140 shares during the period. Mather Group LLC. grew its stake in shares of Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 143 shares during the period. Finally, Exchange Traded Concepts LLC grew its stake in shares of Integer by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,800 shares of the medical equipment provider’s stock valued at $769,000 after buying an additional 145 shares during the period. 99.29% of the stock is owned by institutional investors.

Integer Price Performance

Integer stock opened at $122.87 on Thursday. Integer Holdings Co. has a 52 week low of $107.11 and a 52 week high of $146.36. The company’s 50 day moving average price is $136.01 and its two-hundred day moving average price is $132.95. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The stock has a market cap of $4.13 billion, a P/E ratio of 36.57, a P/E/G ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. On average, equities analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on ITGR shares. Truist Financial raised their target price on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. KeyCorp raised their target price on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Finally, Benchmark raised their target price on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.67.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.